| ||||||||||||||
|
|
|||||||||||||


*Department of Anesthesiology and
Surgery, Tri-Service General Hospital; and
School of Public Heath, National Defense Medical Center, National Defense University, Taipei, Taiwan, Republic of China
Address correspondence and reprint requests to Chi-Yuan Li, MD, MS, Department of Anesthesiology, Tri-Service General Hospital, #325, Section 2, Cheng-Gong Rd., 114 Nei-Hu Dist, Taipei, Taiwan, Republic of China. Address e-mail to cyli{at}ndmctsgh.edu.tw.
Cardiopulmonary bypass (CPB) induces neutrophil activation, degranulation, and a systemic inflammatory response. Matrix metalloproteinase (MMP)-9 exists in neutrophils and is released on neutrophil activation. Increased levels of MMP-9 have been observed in patients undergoing CPB. We designed the present study to determine whether MMP-9 is derived from neutrophils during CPB. Twenty-one patients undergoing elective coronary artery bypass grafting with or without CPB were included in this study. Blood was collected and analyzed for MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1. Neutrophils were also isolated and examined for MMP-9 production and mRNA expression. Plasma levels and activity of MMP-9 increased significantly 26 h after beginning CPB, whereas the MMP-9 levels in patients with off-pump cardiac surgery did not increase. The neutrophil content of MMP-9 and mRNA increased significantly 2 h after beginning CPB. The plasma levels of TIMP-1 increased gradually for 6 h, whereas the MMP-9/TIMP-1 ratios were increased 24 h after beginning CPB. The present study demonstrated that CPB causes an increase in the concentration and activity of plasma MMP-9. The corresponding increase in neutrophil MMP-9 expression and production suggests that MMP-9 is derived primarily from neutrophils and may contribute to the inflammatory response associated with CPB.
This article has been cited by other articles:
![]() |
F. G. Spinale, C. N. Koval, A. M. Deschamps, R. E. Stroud, and J. S. Ikonomidis Dynamic Changes in Matrix Metalloprotienase Activity Within the Human Myocardial Interstitium During Myocardial Arrest and Reperfusion Circulation, September 30, 2008; 118(14_suppl_1): S16 - S23. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aharinejad, K. Krenn, A. Zuckermann, R. Schafer, P. Paulus, G. Seebacher, E. Wolner, and M. Grimm Matrix metalloproteases and their tissue inhibitor in cardiac transplantation Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 48 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. Stacy, Q. Yu, K. Horak, and D. F Larson Effect of angiotensin II on primary cardiac fibroblast matrix metalloproteinase activities Perfusion, January 1, 2007; 22(1): 51 - 55. [Abstract] [PDF] |
||||
|